Marquette University

e-Publications@Marquette
Biomedical Sciences Faculty Research and
Publications

Health Sciences, College of

9-1-2014

Cyclic Ovarian Hormone Modulation of
Supraspinal Δ9-tetrahydrocannabinol-induced
Antinociception and Cannabinoid Receptor
Binding in the Female Rat
Alexa A. Wakley
Washington State University

Alisha A. McBride
Washington State University

Linda K. Vaughn
Marquette University, linda.vaughn@marquette.edu

Rebecca M. Craft
Washington State University

Accepted version. Pharmacology Biochemistry and Behavior, Vol. 124 (September 2014): 269-277.
DOI. © 2014 Elsevier. Used with permission.

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Cyclic Ovarian Hormone Modulation
of Supraspinal Δ9Tetrahydrocannabinol-Induced
Antinociception and Cannabinoid
Receptor Binding in the Female Rat

Alexa A. Wakley
Department of Psychology, Washington State University
Pullman, WA

Alisha A. McBride
Department of Psychology, Washington State University
Pullman, WA

Linda K. Vaugh
Department of Biomedical Sciences, Marquette University
Milwaukee, WI

Rebecca M. Craft
Department of Psychology, Washington State University
Pullman, WA

Pharmacology Biochemistry and Behavior, Vol 124, (September 2014): pg. 269-277. DOI. This article is © Elsevier and
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

1

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Abstract: Estrous cycle-related fluctuations in delta-9-tetrahydrocannabinol
(THC)-induced antinociception have been observed in the rat. The aim of this
study was to determine which major ovarian hormone modulates the
antinociceptive effects of i.c.v. THC, and whether hormone modulation of
THC's behavioral effects could be due to changes in brain cannabinoid
receptors (CBr). Vehicle (oil) or hormones (estradiol or progesterone, or both)
were administered to female rats on days 3 and 7 post-ovariectomy. On the
morning or afternoon of day 8 or day 9, vehicle or THC (100 μg) was
administered i.c.v. Paw pressure, tail withdrawal, locomotor activity and
catalepsy tests were conducted over a 3-h period. Estradiol (with and without
progesterone) enhanced THC-induced paw pressure antinociception only.
Ovarian hormones time-dependently modulated CBr in brain structures that
mediate antinociception and locomotor activity, but the changes observed in
CBr did not parallel changes in behavior. However, the time course of CBr
changes must be further elucidated to determine the functional relationship
between receptor changes and antinociceptive sensitivity to THC.
Keywords: Hormone. Female. Cannabinoid. Antinociception, Locomotion,
Radioligand binding

1. Introduction
Behavioral effects of cannabinoids are sexually dimorphic, with
female rats being more sensitive than males to the reinforcing,
antinociceptive, sedative and cognition-impairing effects of
cannabinoids (Tseng and Craft, 2001; Romero et al., 2002; Cha et al.,
2007; Fattore et al., 2007; Craft and Leitl, 2008; Wakley and Craft,
2011; Craft et al., 2012). Sex differences in antinociceptive response
to cannabinoids such as delta-9-tetrahydrocannabinol (THC) may be
explained by ovarian hormones. Estradiol (E2) enhanced systemic
THC-induced antinociception in ovariectomized (OVX) females
compared to OVX females without hormone replacement (Craft and
Leitl, 2008). This enhancement was similar to that observed in
gonadally intact females tested in estrus vs. those tested in diestrus
(Craft and Leitl, 2008). Estrous stage also modulates antinociception
following supraspinal THC administration: females in late proestrus
showed greater paw pressure antinociception than females in estrus
and males (Wakley and Craft, 2011). These studies demonstrate that
ovarian hormones likely contribute to sex and estrous stage-related
differences in cannabinoid antinociception.
Ovarian hormones also influence endocannabinoid signaling. E2
decreased pituitary cannabinoid receptor (CBr) mRNA levels in OVX
females (González et al., 2000). Similarly, acute E2 decreased Gα
protein activation in the cortex and hippocampus of prepubescent
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female rats (Mize and Alper, 2000). In the limbic forebrain,
ovariectomy decreased, and E2 increased CBr density (Bonnin et al.,
1993; Rodriguez De Fonseca et al., 1994). Similarly, ovariectomy
decreased CBr density in amygdala but increased it in the
hypothalamus and hippocampus; E2 reversed these changes (Riebe et
al., 2010). The other major ovarian hormone, progesterone (P4),
increased CBr density in the limbic forebrain and midbrain but
decreased it in the striatum of OVX females; however, when P4 was
given with E2, hypothalamic CBr density was increased (Rodriguez De
Fonseca et al., 1994), suggesting that P4 can reverse E2's effects.
Although hormone modulation of the brain endocannabinoid system is
a likely mechanism underlying ovarian hormone enhancement of the
behavioral effects of cannabinoids in females, hormone effects appear
to be brain structure-dependent and hormone-specific.
Previous studies examining ovarian hormone modulation of the
endocannabinoid system and the behavioral effects of cannabinoids
have used hormone regimens that do not mimic natural hormone
fluctuations in a gonadally intact female. Typically, a single hormone
was administered, and effects were examined at a single time point
thereafter (Bonnin et al., 1992, 1993; Rodriguez De Fonseca et al.,
1994; Craft and Leitl, 2008; Kalbasi Anaraki et al., 2008; Riebe et al.,
2010). During the 4- to 5-day estrous cycle of a rat, E2 and P4 peak in
early and late proestrus, respectively (Smith et al., 1975; Feder,
1981; Freeman, 1988). Thus, in the present study a modified cyclic
hormone regimen (Asarian and Geary, 2002) was used to determine
which ovarian hormone is responsible for the enhanced supraspinal
THC-induced antinociception previously observed in gonadally intact,
late proestrous females (Wakley and Craft, 2011). The goals of the
present research were to determine if: 1) E2, P4 or both are
responsible for increased supraspinal THC-induced antinociception;
and 2) cyclic ovarian hormones modulate CBr density/affinity in brain
areas known to mediate antinociception.

2. Materials and methods
To examine cyclic ovarian hormone modulation of THC's effects
in females, we measured the effect of i.c.v. THC on antinociception
and motor behavior (Experiment 1), and on CBr density and affinity in
brain structures known to mediate antinociception and motor behavior
(Experiment 2). A third experiment was conducted to measure actual
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serum hormone levels in females treated with the cyclic hormone
regimen.

2.1. Subjects
Adult female Sprague–Dawley rats were used (60–100 days old,
bred in-house from Taconic stock, Germantown, NY). Ad libitum access
to food and water was provided except during surgery and testing.
Rats were housed in a room with a 12:12 h light/dark cycle (lights on
at 0600 h), maintained at 21 ± 2°C. Pair-housing was implemented
until surgery, after which rats were singly housed to avoid damage to
the intracranial implant. This housing procedure was also implemented
for rats used in Experiments 2 and 3. Animals were treated in
accordance with the Guide for the Care and Use of Laboratory Animals
(National Research Council, 2011).

2.2. Surgery
All rats were ovariectomized as described previously (Stoffel et
al., 2003; Craft and Leitl, 2008). For Experiment 1 only, a guide
cannula was also surgically implanted into the right lateral ventricle of
all rats. First, s.c. chlordiazapoxide (3 mg/kg; Sigma Aldrich, St. Louis,
MO) and pre-operative morphine (0.5 mg/kg; Sigma Aldrich, St. Louis,
MO) were injected; 15 min later, rats were anesthetized with
90 mg/kg ketamine hydrochloride plus 10 mg/kg xylazine i.p.
(Webster Veterinary Supply Inc., Kansas City, MO). A 22-gauge
cannula (Plastics One, Roanoke, VA) was implanted into the right
lateral ventricle (AP—1.3 mm; ML—1.8 mm; DV—3.4 mm) (Krivsky et
al., 2006; Paxinos and Watson, 2007). Surgery duration was
approximately 20 and 25 min for ovariectomy and cannula guide
implantation, respectively. Post-operative morphine (2.0 mg/kg) then
was administered. Behavioral testing (Experiment 1) or tissue and
serum collection (Experiments 2 and 3) occurred 8–9 days after
surgery.

2.3. Cyclic hormone administration
Estradiol-3-benzoate (E2) and progesterone (P4; Steraloids,
Newport, RI) were dissolved in safflower oil, which served as the
vehicle for both hormones. Vehicle and hormones were administered in
a 0.1-mL volume. In all experiments, on post-surgery days 3 and 7 at
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0700 h, either safflower oil (vehicle control) or E2 (2 μg) was
administered s.c. to each female. Ten hours later, a second s.c.
injection of either safflower oil or P4 (500 μg) was administered (see
Fig. 1). This cyclic hormone regimen was based on one used by
Asarian and Geary (Asarian and Geary, 2002) to mimic the natural
fluctuation of E2 in gonadally intact, cycling females; the regimen was
modified to include a P4 injection to also mimic fluctuating P4 levels
found in cycling females. P4 was administered 10 h after E2 based on
previous research showing that P4 levels peak 8–12 h after E2 levels
in gonadally intact, cycling female rats. (Smith et al., 1975; Feder,
1981; Freeman, 1988; Haim et al., 2003) Rats in Experiment 1 were
randomly assigned to one of four hormone conditions (oil + oil,
oil + P4, E2 + oil, or E2 + P4) and rats in Experiment 2 were randomly
assigned to one of two hormone conditions (oil + oil or E2 + P4) based
on results from Experiment 1. All rats in Experiment 3 were treated
with both E2 and P4.

Fig. 1. Schematic representation of procedure for behavioral experiment (Experiment
1). On post-surgery days 3 and 7, females were given s.c. injections (dashed arrows)
of oil or estradiol (E2) at 0700 and then 10 h later (1700) given oil or progesterone
(P4). On days 8 and 9, separate groups of females were tested at 0800 and 1500
(solid arrows).

2.4. Experiment 1: Cyclic ovarian hormone modulation
of ICV THC antinociception and motor behavior
Once two cycles of hormones were given (post-surgery days 3
and 7), behavioral testing was conducted at one of three time points
following the last hormone (or oil) injection (see below). Each rat was
tested in only one hormone condition, with either vehicle or THC, at
one of the three time points. Rats were tested starting at 15 h (0800 h
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on post-surgery day 8: “day 8, AM”), or 22 h (1500 h on post-surgery
day 8: “day 8, PM”), or 39 h (0800 h on post-surgery day 9: “day 9,
AM”) after the last hormone (or oil) injection (see Fig. 1). These time
points were chosen to capture the onset and offset of hormonal
modulation of supraspinal THC-induced antinociception, based on a
pilot study. There were 12–13 rats in each vehicle-treatment group
and 15–16 rats in each THC-treatment group (day, dose, hormone
condition) that were included in the final analysis. Baseline latency to
respond was obtained by testing each subject on the tail withdrawal
and paw pressure assays in that sequence, three times. For the tail
withdrawal assay, the distal 5 cm of the tail was submerged in a
50 ± 0.5 °C warm water bath (2.5-L; Precision Scientifics Inc.,
Winchester, VA) and latency to withdraw the tail was measured to the
nearest 0.01 s using a stopwatch. A cutoff of 20 s was used to avoid
tissue damage. Paw pressure antinociception was assessed using an
Analgesy-meter (Ugo-Basile, Varese, Italy). The pressure on the paw
began at 30 g and increased at a constant rate of 48 g/s to a
maximum of 990 g (20 s). Latency to withdraw or attempt to withdraw
the hindpaw was measured to the nearest 0.1 s and a cutoff of 20 s
was used.
After baseline testing, vehicle (1:1:8 ethanol/cremophor/saline)
or 100 μg THC (National Institute on Drug Abuse, Bethesda, MD) was
administered i.c.v. in a volume of 5 μL, at a rate of 20 μL/min; the
injector was left in place for 1 min following infusion to reduce
backflow up the cannula. Only one dose of THC was examined due to
solubility limitations. Rats were then tested for tail withdrawal and paw
pressure antinociception at 5, 15, 30, 60, 120 and 180 min postinjection. Horizontal locomotor activity was measured using a
photobeam apparatus (Opto-varimex, Columbus Instruments,
Columbus, OH) in which 15 photobeams (spaced 2.5 cm apart and
8 cm above the cage floor) cross the width of a 20 × 40 × 23-cm clear
Plexiglas rodent cage. Locomotor activity was measured as the number
of photobeams broken in a 5-min period, beginning immediately after
nociceptive testing at 15, 30, 60, 120 and 180 min post-injection.
Catalepsy (cutoff of 12 s) was assessed at 15 and 30 min postinjection only, to avoid practice effects. For the catalepsy test, the
rat's forepaws were placed on a bar (ring stand with a 1.5-cm
diameter horizontal bar set at approximately 12 cm above the table
surface) and latency to remove both paws from the bar or jump onto
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the bar was recorded to the nearest 0.01 s. Rats were returned to
their home cage between testing periods.
Five to 10 min prior to the first baseline test and immediately
after all behavioral testing was complete, a vaginal cell sample was
obtained from each female via lavage to verify hormone manipulation.
Proestrus (Pro) was identified by the predominance (approximately
75% or more of cells in the sample) of nucleated epithelial cells;
proestrus to estrus (P/E, sometimes referred to as “late proestrus”)
(Bradshaw et al., 2006) was identified by approximately equal
proportions of nucleated and cornified epithelial cells; estrus (Est) was
identified by the presence of dense sheets of cornified epithelial cells;
and diestrus (Diest) was identified by scattered nucleated and cornified
epithelial cells and leukocytes (diestrus-1) or a relative lack of any
cells (diestrus-2) (Freeman, 1988).
Following the last vaginal lavage, rats were euthanized and then
decapitated. Giemsa dye (~ 0.10 mL, Sigma-Aldrich, St. Louis, MO)
was injected into the cannula and the brain was extracted and
sectioned to verify cannula placement. Uteri were harvested, fixed in
10% formalin, and later trimmed and weighed.

2.5. Experiment 2: Membrane preparation and
[3H]SR141716A binding assays
Based on the results from the behavioral experiment
(Experiment 1), tissue for the radioligand binding study was taken
from separate groups of oil + oil-treated and E2 + P4-treated rats,
either 15 h (0800 h on post-surgery day 8: “day 8, AM”—when
hormone enhancement of THC's effect was first observed) or 46 h
(1500 h on post-surgery day 9: “day 9, PM”—when hormone
enhancement of THC's effect was no longer evident) after the last oil
or hormone injection. Brains were quickly removed and placed on ice.
The caudate putamen, hypothalamus, amygdala, periaqueductal gray
(PAG) and cerebellum were immediately dissected. These structures
were chosen because they have been shown to mediate cannabinoid
antinociception (Lichtman et al., 1996; Martin et al., 1999) and
motoric effects (Gough and Olley, 1977; Dar, 2000; Shi et al., 2005).
Tissues were frozen in liquid nitrogen and stored at − 80 °C until
protein estimation and binding was conducted.
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Brain tissues were thawed and homogenized in 700 μL TME
buffer (28 mM Tris–HCl, 22 mM Tris Base, 3 mM MgCl2, 1 mM EDTA,
pH 7.4). PAG tissue was pooled from two females in the same
condition in order to obtain sufficient protein concentration for each
assay. Homogenates were centrifuged twice at 15,000g for 25 min at
4°C and the remaining pellet was re-suspended in the same volume of
TME buffer. Protein concentrations were determined by the Pierce BCA
method (Thermo Scientific, Rockford, IL, USA) using bovine serum
albumin (BSA) as a standard.
Saturation binding analysis was conducted by incubating 25 μg
membrane protein with 0.1–10 nM [3H]SR141716A (Perkin Elmer,
Waltham, MA, USA) in TME buffer containing 0.5 g/L fatty acid free
BSA in a final volume of 0.5 mL (Kearn et al., 1999; Breivogel, 2006;
Wiley et al., 2008). Non-specific binding was determined by the
presence of 1 μM of unlabeled SR141716A (National Institute on Drug
Abuse, Bethesda, MD, USA). Assays were conducted in duplicate and
incubated at 30°C for 60 min (with gentle agitation). Using a harvester
(Brandel, Gaithersburg, MD, USA), incubation was terminated by rapid
filtration under vacuum through Whatman GF/B glass fiber filters that
had been soaked in TME buffer containing 5 g/L fatty acid free BSA.
Filters were washed three times with ice-cold TME buffer containing
2 g/L fatty acid free BSA. Bound radioactivity was determined by liquid
scintillation spectrophotometry at 60% efficiency for 3H after
extraction of the filters in 3 mL of scintillation fluid (EcoScint, National
Diagnostics, Atlanta, GA, USA). Bmax (maximal binding site density)
and KD (equilibrium dissociation constant) were determined by
nonlinear curve fitting of data to the one-site binding equation (Sigma
Plot Version 11.0).

2.6. Experiment 3: Radioimmunoassays to determine
serum hormone levels
To examine E2 and P4 serum levels at various time points after
injection, a separate group of females was treated with two cycles of
E2 + P4 as described above. Trunk blood was taken from 6–8
rats/time point, at the same times that behavioral testing was
conducted (15, 22, 39, and 46 h after the last hormone/oil injection),
plus at several earlier time points (4 and 6 h after the last E2 and P4
injections), to capture peak hormone levels. Blood samples were
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centrifuged for 20 min at 2000 rpm at 4°C; serum was removed and
stored at − 80°C until analysis. Hormone levels were determined via
double antibody radioimmunoassay kits (estradiol (Cat # KE2D1) and
progesterone (Cat # TKPG1): Siemens Healthcare Diagnostics, Los
Angeles, CA, USA). Manufacturer's instructions were followed except
for the E2 assay, in which samples and standards were extracted twice
using methyl tert butyl ether (done in duplicate); after the ether
evaporated, the antibody was added to the extraction tubes, which
were incubated for 24 h at 4°C, followed by addition of the tracer and
then overnight incubation.

2.7. Data analysis
In Experiment 1, only data from rats determined to have
accurate cannula placements were included in analyses (N = 19 were
removed). If post-injection backflow of fluid (possibly vehicle or THC)
from the cannula was observed and less than 40% antinociception was
observed on either nociceptive assay, all data from that rat were
removed before any analysis (N = 2 from oil + oil group; N = 7 from
E2 + oil group; N = 6 from oil + P4 group; N = 3 from E2 + P4
group). Vaginal samples from three females treated with oil + oil or
oil + P4 indicated that they were in proestrus or estrus during testing,
suggesting that an ovary was not fully removed; all data from these
rats were removed before analysis. Baseline nociceptive latencies for
each rat on the tail withdrawal and paw pressure tests were calculated
as the mean of the three pre-injection trials. Individual nociceptive
response latencies following vehicle or drug administration were
converted to % maximum possible effect (%MPE): (drug
latency − baseline latency)/(cutoff latency − baseline latency) × 100.
Time course %MPE data for both tail withdrawal and paw pressure
were converted to area-under-the-curve (AUC) values using the
trapezoidal rule. Because there were differences in locomotor activity
across days in vehicle-treated rats, locomotor activity data in THCtreated rats were converted to % control, on each test day: (#
photobeam breaks in THC-treated rat/mean # photobeam breaks in
same-hormone, same-day, vehicle-treated control group) × 100.
Percent of control locomotor activity data were also converted to AUC
values. A catalepsy score for each rat was obtained by averaging
response latencies at 15 and 30 min post-injection. Some rats
displayed behaviors that were incompatible with catalepsy (i.e., barrel
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rolling, horizontal rocking, loss of muscle tone, lateral head movement
or alternating forepaw movements) at one time point; for those rats a
single catalepsy score was used for analysis. Because there were
significant differences in catalepsy scores among vehicle-treated rats
in the different hormone groups, catalepsy scores were converted to
difference scores (catalepsy score for each THC-treated rat − mean
catalepsy score for vehicle-treated controls in the same hormone
group) before analysis. To control for differences in uterine weight that
were due to differences in body weight, uterine weights (g) were
divided by the rat's body weight in kg, before analysis.
For Experiment 1, antinociception AUC values and uterine
weight were analyzed using a four-way ANOVA: day (3 levels), THC
dose (2 levels), E2 (2 levels), and P4 (2 levels). Locomotor AUC values
and catalepsy data were analyzed using a three-way ANOVA: day (3
levels), E2 (2 levels), and P4 (2 levels). Post-hoc comparisons were
conducted using Bonferroni for comparison across days or two-way
ANOVA for comparisons across hormone groups at different time
points.
For Experiment 2, Bmax and KD values for each brain structure
were analyzed using a two-way ANOVA: day (2 levels) and hormone
treatment (2 levels). Post-hoc comparisons were conducted using ttests to compare across day and hormone treatment. For Experiment
3, a one-way ANOVA was used to compare serum levels of each
hormone over time. Significance level was P ≤ 0.05 for all statistical
tests.

3. Results
3.1. Experiment 1: Cyclic ovarian hormone modulation
of THC's effects on antinociception and motor behavior
3.1.1. Baseline (non-drug) responding
Average baseline tail withdrawal latency across all groups was
5.53 ± 0.04 s. Baseline tail withdrawal latency significantly differed
between rats tested on different days (data not shown; F(2,
133) = 3.69, P < 0.05): tail withdrawal latencies in rats tested on day
8, PM (5.69 ± 0. 12) were higher than those tested on day 9, AM
(5.24 ± 0.12) (P < 0.05). However, when tail withdrawal latencies
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were compared across the 180-min test period in rats given vehicle
(1:1:8 ethanol/cremophor/saline), latency did not differ significantly
among the four hormone groups on any of the test days. Average
baseline paw pressure latency across all groups was 4.31 ± 0.04 s and
did not differ significantly among rats tested on the different days or
given different hormones. Additionally, paw pressure latency did not
differ in vehicle-treated rats across the 180-min test period regardless
of hormone group or test day.

3.1.2. Antinociception
Fig. 2A shows i.c.v. THC-induced tail withdrawal antinociception
in OVX females treated with oil, E2, P4, or both hormones, and tested
15, 22, or 39 h after the last hormone or oil injection (i.e., on postsurgery day 8, AM, day 8, PM or day 9, AM). THC produced tail
withdrawal antinociception (THC dose: F(1, 310) = 246.74,
P < 0.001). Neither hormone, given alone or in combination, altered
THC-induced tail withdrawal antinociception on any of the test days
examined, nor were any significant interactions observed. Although P4
appeared to blunt THC-induced tail withdrawal antinociception on day
8, AM (Fig. 2A), this effect was not statistically significant (P4 × THC
dose × day: F(2, 310) = 0.55, ns). Fig. 2B shows that i.c.v. THC
produced paw pressure antinociception (THC dose: F(1,
310) = 250.03, P < 0.001). E2 significantly enhanced THC's
antinociceptive effect (E2 × THC dose: F(1, 310) = 4.33, P < 0.05),
with no significant day or P4 interactions (E2 × THC dose × day: F(2,
310) = 0.17, ns; E2 × P4 × THC dose × day: F(2, 310) = 0.98, ns).

Fig. 2. Area-under-the-curve (AUC) values for i.c.v. THC-induced tail withdrawal (A)
and paw pressure (B) antinociception in cyclic hormone groups tested 15, 22, or 39 h
after the last hormone (or oil) injection (i.e., on post-surgery day 8, AM, day 8, PM or
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day 9, AM). Each bar is the mean ± 1 SEM of 12–16 rats. When collapsed across days
and E2 group (E2 alone and E2 + P4), E2 significantly enhanced paw pressure
antinociceptive effect of THC (P < 0.05).

3.1.3. Locomotor activity
Locomotor activity in vehicle-treated rats differed among groups
tested at each day (data not shown; day: F(2, 310) = 8.43,
P < 0.001). Specifically, locomotor activity was significantly lower on
day 8, PM than on day 8, AM (P < 0.001) and on day 9, AM
(P < 0.05). Neither hormone significantly altered locomotor activity
AUC values on any test day, nor were any significant interactions
observed (Fig. 3A; E2 × P4 × day: F(2, 177) = 0.20, ns; P4 × day:
F(2, 177) = 1.15, ns).

Fig. 3. Area-under-the-curve (AUC) values for i.c.v. THC-induced locomotor
suppression (A) and catalepsy difference scores 15–30 min after i.c.v. THC (B) in
cyclic hormone groups tested 15, 22, or 39 h after the last hormone (or oil) injection
(i.e., on post-surgery day 8, AM, day 8, PM or day 9, AM). Locomotor data are
presented as the percentage of same-hormone group, vehicle-treated controls.
Catalepsy data are presented as the difference scores between THC-treated rats and
vehicle-treated controls (see Data Analysis section). Each bar is the mean ± 1 SEM of
12–16 rats.

3.1.4. Catalepsy
Average time spent on the bar for i.c.v. vehicle-treated females
in the oil + oil, oil + P4, E2 + oil and E2 + P4 groups across all days
was 1.10 ± 0.09, 1.16 ± 0.09, 1.33 ± 0.13 and 1.50 ± 0.16 s,
respectively. E2-induced increases in time spent on the bar were
significant in i.c.v. vehicle-treated females (Fig. 3B; E2: F(1,
120) = 4.45, P < 0.05). Fig. 3B shows the catalepsy difference scores
for THC-treated females. Neither hormone, given alone or in
combination, significantly altered THC-induced catalepsy on any day,
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nor were there any significant interactions. It should be noted that
other motoric effects of THC were observed in some rats: barrel-rolling
or involuntary spinning of the whole body (Kelly et al., 1977; Wakley
and Craft, 2011), and/or horizontal rocking and loss of muscle tone
were observed in 33% of rats given THC (Table 1). Although barrel
rolling was observed in 25% of the E2 + P4-, THC-treated rats,
approximately 18% of the oil + oil-, THC-treated rats displayed the
same behavior.
Table 1. Percent of THC-treated rats showing various motoric effects during
the 15- and/or 30-min post-injection catalepsy measurements (# rats
showing behavior/total # rats tested), and catalepsy score (mean ± 1 SEM, in
seconds).
Behavior
Loss of muscle
tonea
Horizontal
rockingb
Barrel-rollingb

Oil + Oil

Oil + P4

E2 + Oil

E2 + P4

4.3% (2/47)

10.9% (5/46)

10.4% (5/48)

8.3% (4/48)

8.5% (4/47)

4.3% (2/46)

18.8% (9/48)

2.1% (1/48)

19.0% (9/47)
6.5% (3/46)
10.4% (5/48)
25.0% (12/48)
2.83 ± 0.33
2.81 ± 0.39
3.98 ± 0.41
3.66 ± 0.39
Catalepsyb
(46/47)
(46/46)
(46/48)
(46/48)
aRat slipped off bar immediately after forepaws were placed on bar.
bBehaviors are not mutually exclusive; i.e., a rat could show both loss of muscle tone
and barrel-rolling behavior.

3.1.5. Supraspinal effects of THC 46 h after the last hormone
injection (day 9, PM)
Because enhancement of paw pressure antinociception persisted
out to day 9, AM, in E2 + P4-treated females (Fig. 2B), separate
groups of females were treated with oil + oil or E2 + P4 and then were
tested 46 h after the last hormone injection (day 9, PM) to determine
if this enhancement waned. On day 9, PM, tail withdrawal and paw
pressure AUC values were comparable between oil + oil and E2 + P4
rats (data not shown; hormone × THC dose: F(1, 52) = 0.85, ns for
tail withdrawal; hormone × THC dose: F(1, 52) = 0.05, ns for paw
pressure). Similarly, no hormone effects on THC-induced locomotor
suppression or catalepsy were observed (data not shown;
hormone × THC dose: F(1, 52) = 0.01, ns for locomotor activity;
hormone × THC dose: F(1, 52) = 0.75, ns for catalepsy). However,
uterine weights of E2 + P4-treated females were still significantly
increased compared to oil + oil-treated rats on day 9, PM (data not
shown; hormone: F(1, 52) = 210.81, P < 0.001). Finally, on day 9,
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PM, 54% of E2 + P4-treated rats were in Pro, 32% were in Est, and
the remaining 14% were in P/E.

3.1.6. Vaginal cytology
Vaginal cytology was assessed both before and after the 3-h
test period to obtain additional information regarding hormone status.
Fourteen percent of females did not show the same vaginal cytology
from pre-test to post-test and in these cases the pre-test cytology was
used. Table 2 shows the percent of rats in each estrous stage in each
hormone group across different test days. Oil-treated females
(oil + oil) and P4-treated females (oil + P4) were all in the expected
stage: 100% of all samples were diestrus (Diest). In contrast,
approximately 75% of E2-treated rats (E2 + oil) were in proestrus
(Pro) on day 8 (both AM and PM) with the remaining rats in either
proestrus/estrus (P/E) or estrus (Est). On day 9, AM, E2-treated rats
were predominately in Est (79%) with only 14% of samples showing
vaginal cytology indicative of Pro. A majority of the rats (61%) treated
with both E2 and P4 were in Pro on day 8, AM, with the remaining in
either P/E or Est. However, only 21% of E2 + P4-treated rats tested
on day 8, PM were in Pro; 50% were in Est. On day 9, AM, 78% of
E2 + P4-treated rats were in either Pro or Est.
Table 2. Pre-test estrous stage of rats in each hormone group, as % of rats
showing vaginal cytology indicative of proestrus (Pro), proestrus/estrus (P/E),
estrus (Est), or diestrus (Diest) (N = 28–29 rats/hormone group/day).
Hormone treatment
Oil + Oil
Oil + P4
E2 + Oil
E2 + P4

Day
Pro
0
0
75
61

8, AM
P/E Est
0
0
0
0
14 11
18 21

Diest
100
100
0
0

Day
Pro
0
0
72
21

8, PM
P/E Est
0
0
0
0
14 14
11 68

Diest
100
100
0
0

Day
Pro
0
0
14
39

9, AM
P/E Est
0
0
0
0
4
82
14 47

Diest
100
100
0
0

3.1.7. Uterine weight
Fig. 4 shows that E2 significantly increased uterine weight (E2:
F(1, 310) = 1611.37, P < 0.001). P4 attenuated E2's effect on uterine
weight (E2 × P4: F(1, 310) = 13.01, P < 0.001). Females given THC
also had lower uterine weights compared to those given vehicle (THC
dose: F(1, 310) = 4.04, P < 0.05).

Pharmacology Biochemistry and Behavior, Vol 124, (September 2014): pg. 269-277. DOI. This article is © Elsevier and
permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission
for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

14

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Fig. 4. Uterine weight (g/kg body weight) of cyclic hormone-treated OVX rats tested
15, 22, or 39 h after the last hormone (or oil) injection (i.e., on post-surgery day 8,
AM, day 8, PM or day 9, AM). Each bar is the mean ± 1 SEM of 12–16 rats.

3.2. Experiment 2: Cyclic ovarian hormone modulation
of CBr receptor binding and affinity
Fig. 5 shows Bmax values and Table 3 shows KD values, for oilvs. hormone-treated groups when brain tissue was harvested on day
8, AM, or day 9, PM. These two time points were chosen as the earliest
time at which hormone enhanced THC-induced antinociception and a
later time point at which hormone had no effect on THC-induced
antinociception in Experiment 1. Fig. 5A shows that in the PAG,
E2 + P4 treatment increased Bmax on day 9, PM compared to oil-treated
controls (hormone × day: F(1, 26) = 4.40, P < 0.05). Additionally,
Bmax was decreased in day 9, PM oil-treated controls compared to day
8, AM oil-treated controls (t(14) = 2.65, P < 0.05). In the PAG,
changes in Bmax were not accompanied by changes in KD values
(Table 3; hormone × day: F(1, 26) = 0.33, ns). Conversely, in the
amygdala, neither day nor hormone treatment significantly affected
Bmax or KD values (Fig. 5B and Table 3; all Ps > 0.05).
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Fig. 5. Maximum binding capacity (Bmax) of cannabinoid receptors (CBr) in
the periaqueductal gray (A), amygdala (B), caudate putamen (C), cerebellum
(D) and hypothalamus (E) of OVX female rats treated with cyclic oil + oil or
E2 + P4. Brain tissue was harvested 15 h (day 8, AM) or 46 h (day 9, PM)
after the last oil or hormone injection. Each bar is the mean ± 1 SEM of 6–9
rats/hormone group. *Significantly different from same-day, oil-treated
females, P < 0.05. #Significantly different from oil-treated day 8, AM
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females, P < 0.05. Note: The y-axis scale of cerebellum (D) is larger than
other brain regions due to high density of CBr found in this structure.

Table 3. Binding affinity of [3H]SR141716A (nM, mean ± 1 SEM) in
OVX female rats treated with cyclic oil + oil or E2 + P4.
Day

Day 8,
AM

Day 9,
PM

Hormone
group
Oil + Oil
E2 + P4
Oil + Oil
E2 + P4

Brain structure
Caudate
Amygdala
Putamen
0.39 ±
0.45 ± 0.04
0.02
0.38 ±
0.35 ± 0.04
0.04
0.40 ±
0.54 ± 0.06*
0.04
0.48 ±
0.45 ± 0.03**
0.06

Hypothalamus PAG
0.36 ± 0.03
0.45 ± 0.09
0.43 ± 0.05
0.40 ± 0.05

0.39
0.04
0.39
0.06
0.34
0.03
0.42
0.05

Cerebellum
±
±
±
±

0.54
0.06
0.41
0.04
0.62
0.07
0.54
0.06

±
±
±
±

Brain tissue collection occurred at 15 h (day 8, AM) or 46 h (day 9, PM) after
the last oil or hormone injection. Each bar is the mean ± 1 SEM of 6–9
rats/hormone group.
*Significantly different from oil-treated day 8, AM females, P < 0.05.
**Significantly different from same-day, oil-treated females, P < 0.05.

Fig. 5C shows that in the caudate putamen, E2 + P4 treatment
decreased Bmax compared to oil-treated controls only on day 9, PM
(hormone × day: F(1, 27) = 4.45, P < 0.05). Unexpectedly, Bmax was
increased in oil-treated day 9, PM females compared to oil-treated day
8, AM females (t(13) = 2.61, P < 0.05). In the caudate putamen,
E2 + P4 treatment also decreased KD compared to oil treatment
(hormone: F(1, 27) = 6.39, P < 0.05), and KD values were decreased
on day 8, AM compared to day 9, PM (Table 3; day: F(1, 27) = 6.06,
P < 0.05). In the cerebellum, E2 + P4 treatment appeared to decrease
Bmax; however, this effect was not significant (Fig. 5D; hormone: F(1,
24) = 2.21, P = 0.15). Neither day nor hormone treatment
significantly altered KD (all Ps > 0.05). Lastly, Fig. 5E and Table 3
show that in the hypothalamus, day and hormone treatment did not
alter Bmax or KD values (all Ps > 0.05).

3.3. Experiment 3: Serum levels of E2 and P4 using a
cyclic hormone regimen
Fig. 6 shows that serum E2 reached peak levels by 16 h after
the s.c. E2 injection given on day 7 at 0700 h, and levels were low by
25 h after injection (time: F(7,47) = 2.99, P < 0.05). Serum P4
reached peak levels by 4 h after the s.c. P4 injection given on day 7 at
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1700 h, and levels declined over the next 18 h (Fig. 6; time:
F(7,49) = 17.96, P < 0.001).

Fig. 6. Serum levels of estradiol (E2; pg/mL) and progesterone (P4; ng/mL)
at various points following hormone injections given on post-OVX day 7. Each
point is the mean ± 1 SEM of 6 rats.

4. Discussion
The present study demonstrates that ovarian hormones alter
sensitivity to supraspinal cannabinoid antinociception in female rats. In
OVX females, E2 enhanced i.c.v. THC-induced mechanical
antinociception, whether E2 was given alone or with P4. THC-induced
antinociception was enhanced approximately 24–48 h after hormone
injection. Ovarian hormones did not significantly modulate THCinduced locomotor suppression or catalepsy, and therefore enhanced
antinociception does not appear to be simply due to enhanced motoric
effects. Ovarian hormones also altered CBr density in PAG and
striatum and CBr affinity in striatum, but these changes did not
parallel behavior in the predicted manner.
The first finding, E2 enhancement of THC-induced mechanical
antinociception, corroborates previous work from our laboratory. We
first reported E2 enhancement of THC-induced antinociception
following systemic THC administration in OVX female rats (Craft and
Leitl, 2008). This hormone enhancement was similar to that observed
in estrous compared to diestrous females receiving i.p. THC (Craft and
Leitl, 2008), and in P/E compared to estrous females and males
receiving i.c.v. THC (Wakley and Craft, 2011). The present study
provides further evidence that E2 can act supraspinally to enhance
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females' response to THC. Together, these studies indicate that sex
and estrous stage differences in cannabinoid antinociception are due to
E2 in females.
In the present study, E2 enhanced only THC-induced mechanical
antinociception. In all of our studies, THC-induced mechanical
antinociception appears to be more sensitive than THC-induced
thermal antinociception to ovarian hormone modulation (Tseng and
Craft, 2001; Craft and Leitl, 2008; Wakley and Craft, 2011; Craft et
al., 2012). E2 modulation of cannabinoid antinociception on one
nociceptive test but not the other may reflect differences in the extent
to which each nociceptive response engages spinal vs. supraspinal
mechanisms. THC-induced tail withdrawal antinociception has been
shown to be more spinally than supraspinally mediated (Smith and
Martin, 1992). There is no direct evidence that the paw withdrawal
response is supraspinally mediated, however, the postural adjustments
required for this response likely involve supraspinal components (e.g.,
cerebellum, basal ganglia). Therefore, it is possible that E2
enhancement of THC-induced antinociception was greater on the paw
pressure than on the tail withdrawal assay due to a larger contribution
of supraspinal mechanisms in the paw withdrawal response, and
greater cannabinoid and/or E2 effects supraspinally than spinally. In
the future, it will be important to determine whether E2 enhancement
of cannabinoid antinociception can also occur at the spinal level, and
whether this phenomenon is sensory modality-specific.
This is the first study to examine the effects of ovarian
hormones on CBr density and affinity in the PAG, a region of the brain
involved in cannabinoid-mediated antinociception (Martin et al., 1995,
1999; Lichtman et al., 1996). We found a significant increase in
receptor density on day 9 PM but not on day 8 AM. Thus, hormoneinduced increases in CBr density did not parallel hormone-induced
increases in behavioral sensitivity to THC. Further work will be
necessary to fully characterize the time course of hormone-induced
brain CBr changes, so that the temporal relationship between
enhanced antinociception and CBr can be more precisely compared.
Also, the effects of E2 alone on binding parameters need to be
determined, as binding results from the present study are limited by
examining only the E2 + P4-treated group. Finally, it is possible that a
change in CBr density is not responsible or only partly responsible for
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E2 enhancement of THC effect. Given the importance of PAG signaling
in the antinociceptive effect of THC (Vaughan et al., 2000), it will be
important to carefully examine the ability of ovarian hormones to
upregulate CBr in this region.
We also found significant ovarian hormone-dependent changes
in binding parameters in the striatum. Interestingly, especially given
the lack of significant interaction between hormones and THC on
locomotor behavior, we found opposing changes in striatal binding
parameters, with hormone decreasing CBr density but increasing
affinity. These changes may be functionally related, with a change in
one variable causing a subsequent response in the other, resulting in
stable cannabinoid signaling. The fact that this ovarian hormone
regimen produced both an increase and decrease in Bmax in different
brain regions indicates that multiple regulatory pathways may be
involved. Finally, we found no changes in CBr density or affinity in the
hypothalamus, amygdala or cerebellum.
Our methodology differs from previous investigations of the role
of ovarian hormones on the regulation of CBr signaling. This is the first
study to demonstrate that a cyclic hormone regimen (to mimic normal
hormone fluctuation) produced changes in CBr density and affinity and
that CBr density changes over time following ovariectomy. Although
the effects of chronic and acute E2 or acute P4 on CBr in different
brain regions have been examined previously (Bonnin et al., 1992,
1993; Rodriguez De Fonseca et al., 1994; Riebe et al., 2010), only one
has examined the combined effects of both ovarian hormones:
E2 + P4 given simultaneously increased CBr density compared to oiltreated controls, but only in the hypothalamus; no significant
differences between the hormone group and oil-treated controls were
observed in any other brain region (Rodriguez De Fonseca et al.,
1994). Furthermore, in the present study, E2 + P4 increased binding
affinity in the caudate putamen, whereas (Rodriguez de Fonseca and
colleagues 1994) did not find group differences in affinity in this brain
region or any other. We utilized a cyclic hormone regimen (2 cycles of
2 μg E2/rat and 500 μg P4/rat, with E2 and P4 given 10 h apart) with
tissue collection at 15- and 46-h after the last hormone injection,
whereas previous work used lower (0.02–0.03 μg E2/rat and 38–50 μg
P4/rat) or higher (10 μg E2/rat) hormone doses; single or concomitant
hormone injections; or a shorter pretreatment time, with tissue
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collection occurring either 1 or 48 h after hormone injections
(Rodriguez De Fonseca et al., 1994; Riebe et al., 2010). Taken
together, the present and previous results suggest that ovarian
hormones regulate expression of cannabinoid receptors in a highly
time- and region-specific manner.
Ovarian hormones could also enhance THC-induced
antinociception through other mechanisms. For example, E2 may
modulate cannabinoid effects through regulating N-type voltage-gated
calcium channels (Lee et al., 2002; Adams et al., 2010) or other
signaling mechanisms in the descending pain pathway to produce
enhancement of THC antinociception. E2 has also been found to
potentiate the presynaptic inhibition of GABA produced by WIN55,212
in proopiomelanocortin neurons of the arcuate nucleus (Nguyen and
Wagner, 2006), although the precise mechanism of this modulation
remains unknown. If E2 produces a similar effect in the PAG, inhibiting
the release of GABA such that output neurons are disinhibited,
antinociception would be enhanced.
Cyclic administration of E2 and P4 was used in the present study
to mimic the normal hormone fluctuation of a gonadally intact cycling
female rat. Although the time course of serum hormone levels was
similar to that observed in cycling females, reproductive tissue indices
revealed that this hormone regimen still was not precisely modeling a
normally cycling female. Normally cycling females show peak levels of
E2 and P4 between 40–45 pg/mL and 50–55 ng/mL, respectively, with
E2 and P4 peaks approximately 8–12 h apart (Smith et al., 1975;
Haim et al., 2003) – which is similar to what we observed in the
present study. However, uterine weights and vaginal cytology did not
show the progressive, rapid changes that are characteristic of cycling
females post-ovulation, but instead were indicative of a lingering E2
presence. Additionally, E2 enhancement of THC-induced
antinociception in OVX females was prolonged compared to that
observed in intact cycling females, occurring up to 49 h after the last
E2 injection. In normal cycling females, the transition from late
proestrus to estrus occurs in approximately 4 h (Feder, 1981) and
enhancement of THC-induced antinociception in late proestrous
females was absent in estrous females (Wakley and Craft, 2011). The
prolonged effects of E2 on antinociception and on reproductive tissue
were likely due to the use of estradiol-3-benzoate, which is longer-
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acting than 17β-estradiol (Becker et al., 2005). Consequently, 17βestradiol should be used to more accurately mimic natural cycling in
females, as this would allow for more accurate characterization ovarian
hormone modulation of drug sensitivity.
In conclusion, the present study shows that the ovarian
hormone E2 enhances female rats' sensitivity to supraspinal
cannabinoid-induced antinociception. Using a cyclic hormone regimen,
we found that E2 alone and in combination with P4 enhanced
mechanical antinociception produced by i.c.v. THC, when THC's effects
were measured approximately one day after E2 administration.
Therefore, previously observed enhancement of i.c.v. THC in
proestrous–estrous females is likely due to estradiol modulation of
supraspinal mechanisms. Ovarian hormones did not modulate THCinduced locomotor suppression or catalepsy, and therefore hormone
effects on motor function do not appear to explain the observed
enhancement of antinociception. Ovarian hormones time-dependently
modulated CBr in brain structures that mediate antinociception and
locomotor activity, but the changes observed in CBr did not parallel
changes in behavior. Definitive causality between the receptor changes
and enhanced sensitivity to THC cannot be ruled out since CBr density
was only measured at the beginning and after the period of enhanced
antinociception, rather than across the entire time course. Examination
of hormone effects on downstream signaling of CBr may yield
additional mechanistic explanations for hormone modulation of
supraspinal cannabinoid effects.
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